Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Don’t Let Trade Issues Interfere With Drug Inspection Coordination, Experts Say

Executive Summary

US National Academies panel diverges on how to focus pharmaceutical inspectorates’ mutual reliance arrangements on public health goals.

You may also be interested in...

Why Now Is The Right Time For Mutual Recognition

20 years later, signs that this time the US EU mutual recognition agreement won’t fizzle.

EU, US Finally Agree On Mutual Recognition Of GMP Inspections

Reliance on each other’s good manufacturing practice reports should allow EU and US regulators to better focus their limited inspection resources on drug manufacturers in other countries around the world.

Achieving A Resilient Flu Vaccine Supply Chain Requires Retooling Most Of The Links

Expert panel draws lessons from COVID-19 in pressing for new manufacturing technologies, greater global coordination, more resilient supply chains and trained vaccine plant workers ready to “parachute” into the next outbreak.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts